The National Health Surveillance Agency (Anvisa) has announced an extension of the deadline for submitting contributions related to the regulation of Law 15.404/2026. The measure aims to provide more time for pharmaceutical sector stakeholders to participate in the discussion and development of the rules that will regulate the aforementioned law.
This action reflects Anvisa's commitment to transparency and the inclusion of different perspectives in the construction of its regulations. By extending the deadline, the agency seeks to ensure that companies, associations, healthcare professionals, and other interested parties can adequately contribute to defining the rules that will govern the sector.
Law 15.404/2026 represents an important update to Brazil's pharmaceutical regulatory framework. The public consultation opened by Anvisa is a fundamental mechanism for society to participate in the construction of public policies that directly impact access to and quality of medicines in the country.
The regulatory process involves rigorous technical analysis of received contributions, considering aspects of safety, efficacy, quality, and compliance with international standards. Anvisa evaluates each submission to ensure that final regulations are appropriate for the Brazilian pharmaceutical market reality, maintaining the highest standards of public health protection.
Those interested in participating in the process can follow information on Anvisa's official website, where they will find details about the new deadline and guidelines for submitting contributions. This openness by the agency to dialogue with the sector is essential for building a more robust regulatory environment aligned with the needs of the national pharmaceutical market.
